<DOC>
	<DOC>NCT00777036</DOC>
	<brief_summary>The purpose of this study is to determine whether dasatinib is safe and effective in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia (ALL), accelerated or blast phases CML who relapse after imatinib or who are resistant or intolerant to imatinib. The side effects of this oral investigational drug in children and adolescents will be evaluated</brief_summary>
	<brief_title>A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib</brief_title>
	<detailed_description>Cohort 2 is closed to enrollment</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. CPCML who prove resistant or intolerant to imatinib (cohort #1) Ph+ ALL, APCML, or BPCML who are resistant or intolerant to or who relapse after imatinib therapy (cohort #2) Newly diagnosed, treatment naive CPCML (cohort #3) Lansky or Karnofsky scale &gt;50 Life expectancy â‰¥12 weeks Adequate hepatic and renal function Written informed consent Eligibility for potentiallycurative therapy including hematopoietic stemcell transplantation Symptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal disease) Isolated extramedullary disease Prior therapy with Dasatinib</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leukemia, Pediatric</keyword>
</DOC>